MX2023012651A - Novedosas composiciones y metodos de n,n-dimetiltriptamina. - Google Patents

Novedosas composiciones y metodos de n,n-dimetiltriptamina.

Info

Publication number
MX2023012651A
MX2023012651A MX2023012651A MX2023012651A MX2023012651A MX 2023012651 A MX2023012651 A MX 2023012651A MX 2023012651 A MX2023012651 A MX 2023012651A MX 2023012651 A MX2023012651 A MX 2023012651A MX 2023012651 A MX2023012651 A MX 2023012651A
Authority
MX
Mexico
Prior art keywords
dmt
dimethyltryptamine
methods
novel compositions
exhibiting
Prior art date
Application number
MX2023012651A
Other languages
English (en)
Spanish (es)
Inventor
Srinivas Rao
Gleen Short
Original Assignee
Atai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atai Therapeutics Inc filed Critical Atai Therapeutics Inc
Publication of MX2023012651A publication Critical patent/MX2023012651A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2023012651A 2021-04-26 2022-04-26 Novedosas composiciones y metodos de n,n-dimetiltriptamina. MX2023012651A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163179679P 2021-04-26 2021-04-26
PCT/US2022/026396 WO2022232179A1 (en) 2021-04-26 2022-04-26 Novel n,n-dimethyltryptamine compositions and methods

Publications (1)

Publication Number Publication Date
MX2023012651A true MX2023012651A (es) 2023-11-06

Family

ID=83694712

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012651A MX2023012651A (es) 2021-04-26 2022-04-26 Novedosas composiciones y metodos de n,n-dimetiltriptamina.

Country Status (12)

Country Link
US (1) US11602521B2 (cg-RX-API-DMAC7.html)
EP (1) EP4329879A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517738A (cg-RX-API-DMAC7.html)
KR (1) KR20240000516A (cg-RX-API-DMAC7.html)
CN (1) CN117320711A (cg-RX-API-DMAC7.html)
AU (1) AU2022267240A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022195A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216889A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003191A1 (cg-RX-API-DMAC7.html)
IL (1) IL308074A (cg-RX-API-DMAC7.html)
MX (1) MX2023012651A (cg-RX-API-DMAC7.html)
WO (1) WO2022232179A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753923A1 (en) 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
KR20250005182A (ko) * 2022-03-27 2025-01-09 지에이치 리서치 아일랜드 리미티드 인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민
EP4608395A2 (en) * 2022-10-26 2025-09-03 ATAI Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
DK202330319A1 (en) * 2023-11-07 2025-05-27 Fertin Pharma As An adhesive oral disc for sustained release of cannabinoids
US20240325351A1 (en) 2023-03-31 2024-10-03 Cybin UK Ltd. Method of administration
EP4773958A1 (en) * 2023-09-08 2026-07-15 ATAI Therapeutics, Inc. Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
EP4788322A1 (en) * 2023-10-02 2026-08-12 ATAI Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60215685A (ja) * 1984-04-11 1985-10-29 Takeda Chem Ind Ltd 2’−デオキシアリステロマイシン誘導体およびその用途
US20220079881A1 (en) 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
DK3927338T3 (da) * 2019-02-22 2025-01-06 Gh Res Ireland Limited Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
HUE066828T2 (hu) 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
KR102946120B1 (ko) * 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
WO2020176597A1 (en) * 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
WO2021003467A1 (en) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US20210023052A1 (en) * 2019-07-23 2021-01-28 Caamtech Llc Compositions containing toad secretion compounds
WO2021041407A1 (en) * 2019-08-25 2021-03-04 Caamtech Llc Alkyl quarternary ammonium tryptamines and their therapeutic uses
CN115297851A (zh) * 2019-12-31 2022-11-04 Tf科技企业 口溶膜及其生产和使用方法
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
EP4167992A1 (en) * 2020-06-22 2023-04-26 University of Zürich Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy
CA3188263A1 (en) * 2020-08-05 2022-02-10 Matthias Emanuel LIECHTI Intravenous dmt administration method for dmt-assisted psychotherapy
CA3192617A1 (en) 2020-09-20 2022-03-24 Matthew BAGGOTT Advantageous tryptamine compositions for mental disorders or enhancement
KR20240013170A (ko) * 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태

Also Published As

Publication number Publication date
JP2024517738A (ja) 2024-04-23
EP4329879A4 (en) 2025-04-09
AU2022267240A1 (en) 2023-11-23
US20220339139A1 (en) 2022-10-27
BR112023022195A2 (pt) 2024-01-16
IL308074A (en) 2023-12-01
CA3216889A1 (en) 2022-11-03
KR20240000516A (ko) 2024-01-02
WO2022232179A9 (en) 2023-07-13
EP4329879A1 (en) 2024-03-06
US11602521B2 (en) 2023-03-14
CN117320711A (zh) 2023-12-29
CL2023003191A1 (es) 2024-04-01
WO2022232179A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
CL2023003191A1 (es) Novedosas composiciones y métodos de n,n-dimetiltriptamina
JP5002114B2 (ja) 亜塩素酸塩および過酸化水素を含有する相乗的抗菌性眼科用および皮膚科用製剤
Straka et al. Periodontitis and stroke
ES2170050T3 (es) Metodos y composiciones para inducir la ereccion.
RU2012136724A (ru) Лечение или профилактика инфекции
JP2020128437A (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物
EA201992759A1 (ru) Ассоциация, включающая кислород и гиалуроновую кислоту, для местного вагинального применения
Stecker et al. Should a mucoadhesive patch (DentiPatch) be used for gingival anesthesia in children?
BR0008443A (pt) Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética
Paraskevas et al. Thromboangiitis obliterans (Buerger’s disease): searching for a therapeutic strategy
RU2550957C1 (ru) Способ лечения хронического генерализованного пародонтита
EA200501456A1 (ru) Торий- 227 для применения в радиотерапии заболевания мягких тканей
CL2022002104A1 (es) Tratamiento de infección por coronavirus con interferón lambda
WO2000018380A1 (en) Prevention and treatment of parodontitis
WO2021107824A1 (ru) Способ фотодинамической терапии заболеваний полости рта и стоматологический гель-фотосенсибилизатор
Al-Zarea et al. Efficacy of Myrrh Mouth Rinse vs. Chlorhexidine Mouth Rinse in Maintaining the Soft Tissue Health around Dental Implants: A Comparative Study.
AR122160A1 (es) PROCEDIMIENTO PARA EL TRATAMIENTO DE UNA INFECCIÓN VIRAL CON a-1-ANTITRIPSINA HUMANA
Butticaz et al. Evaluation of a nystatin-containing mouth rinse for terminally ill patients in palliative care
RU2605260C1 (ru) Способ комплексного лечения больных с воспалительными заболеваниями пародонта
RU2705388C1 (ru) Способ лечения хронического генерализованного катарального гингивита
Poulose et al. A comparative study of Apamarga Kshara Lepa and Jaloukavacharana in the management of Dushta Vrana
da Silva Lemos et al. Sci Forschen
RU2227017C2 (ru) Способ лечения хронических рецидивирующих трещин губ и сочетаний хронических рецидивирующих трещин губ с эксфолиативным или атопическим хейлитами
RU2179841C1 (ru) Способ лечения пародонтоза
RU2643589C1 (ru) Способ лечения острого неспецифического гингивита и хронического гингивита маргинального простого